Loading stock data…
Annexon (ANNX)
$5.54+0.06 (+1.09%)
Market OpenUpdated 3:09 PM EDT
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Annexon, Inc. in the Healthcare sector is trading at $5.48 with a market capitalization of $738M. Wall Street consensus targets $13.12 (8 analysts), implying a +139.5% move over the next 12 months. The stock is currently 24% below its 52-week high of $7.18, remaining 13.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +139.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$46.05M↑ | -$50.26M↑ | -$57.02M↓ | -$51.73M↑ | -$57.41M |
| Net Income | -$44.14M↑ | -$48.26M↑ | -$54.92M↓ | -$49.16M↑ | -$54.36M |
Peer Comparison
JNJUNHPFE
Fundamentals
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinica...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$738.11M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-96.06%
Volume
Today's trading volume
1.50M
Recent News
Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead
Annexon (NASDAQ:ANNX) executives used a Goldman Sachs Healthcare Conference session to outline the company’s upcoming clinical and regulatory catalysts, led by pivotal Phase III data expected in the fourth quarter for vonaprument in geographic atrophy, a form of advanced dry age-related macular dege
Exploring 3 High Growth Tech Stocks in the US Market
Over the last 7 days, the United States market has dropped 2.7%, yet it remains up by 23% over the past year, with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that exhibit strong innovation potential and robust financial health to capitalize on future opportunities.
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
Annexon (NASDAQ:ANNX) executives outlined a series of expected clinical and regulatory updates across the company’s complement-focused pipeline during a session at the Jefferies Conference, highlighting programs in geographic atrophy, Guillain-Barré syndrome and cold agglutinin disease. Douglas Lov
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company’s late-stage pipeline and regulatory plans during a presentation at the Bank of America Healthcare Conference, highlighting upcoming data in geographic atrophy and regulatory filings for Guillain-Barré syndrome. Love described A
Annexon (ANNX): 7 Small Cap Stocks with the Highest Upside Potential
Annexon Inc. (NASDAQ:ANNX) is one of the small cap stocks with the highest upside potential. On March 30, the company reported its 2025 year-end financial results, highlighting a period of significant clinical and regulatory progress for its neuroinflammatory disease platform. The company ended the year with a strong balance sheet featuring $238.3 million in cash […]